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Abstract: 
Objective: Benzodiazepines (BZD) are recommended as first line treatment for status 
epilepticus (SE) with lorazepam (LZP) and midazolam (MDZ) being the most widely used 
drugs and part of current treatment guidelines. Clonazepam (CLZ) is also utilized in many 
countries; however, there is no systematic comparison of these agents for treatment of SE to 
date. 
Methods: We identified all patients treated with CLZ, LZP or MDZ as a first line agent from a 
prospectively collected observational cohort of adult patients treated for SE in four tertiary 
care centers. Relative efficacies of CLZ, LZP, and MDZ were compared by assessing the risk 
of developing refractory SE and the number of anti-seizure drugs (ASDs) required to control 
SE. 
Results: Among 177 patients, 72 patients (40.62%) received CLZ, 82 patients (46.33%) LZP 
and 23 (12.99%) MDZ; groups were similar in demographics and SE characteristics. Loading 
dose was considered insufficient in the majority of cases for LZP, with a similar rate (84%, 
95% and 87.5%) in the centers involved and CLZ was used as recommended in 52% of 
patients. After adjustment for relevant variables, LZP was associated with an increased risk 
of refractoriness as compared to CLZ (OR: 6.4, 95%, CI: 2.66 – 15.5) and with an increased 
number of ASDs needed for SE control (OR: 4.35, 95%, CI: 1.8 - 10.49).  
Significance: CLZ seems to be an effective alternative to LZP and MDZ. LZP is frequently 
under-dosed in this setting.  These findings are highly relevant, since they may impact daily 
practice. 
 
Search term:  
Epilepsy; benzodiazepines; critical care; coma; neurologic emergency 
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Introduction: 
Status epilepticus (SE) is one of the most frequent and serious neurological emergencies 
associated with a mortality between 7 - 33%1,2,3,4. Rapid and effective treatments are needed. 
According to current guidelines5,6, benzodiazepines (BZD) represent the first line of treatment 
because of class I evidence regarding their efficacy in this setting. Intravenous (iv) lorazepam 
(LZP) and midazolam (MDZ) are the most widely used7, likely due to randomized studies 
showing their efficacy8,9,10 in this setting. MDZ was recently identified as the best option for 
out-of-hospital convulsive SE10. However, in many countries worldwide, mostly in Europe, 
such as the Czech Republic, France, Germany, Ireland, Italy, the Netherlands, Spain, 
Sweden, Switzerland, the United Kingdom, Korea, South Africa, and Turkey (iv) clonazepam 
(CLZ) is also registered and used widely for SE treatment11, despite the relatively limited 
evidence supporting its use. In addition in some countries there has been a lack of 
availability of LZP intravenous formulation, leading to the use of alternative compounds. 
As LZP and MDZ, CLZ has a high affinity for the GABAA receptor12. LZP and CLZ are both 
highly lipophilic, allowing rapid onset of effects in the brain13. In addition, CLZ has a much 
longer elimination half-life (between 19 and 60 hours) than LZP (7 to 26 hours) or MDZ (1 to 
4 hours)12,14. Neither LZP, nor CLZ have any active metabolite, whereas the MDZ metabolite 
1-hydroxymidazolam displays an equal activity like midazolam whereby the glucuronidated 1-
OH-midazolam can critically (up to 5-10 times) prolong the sedative action in case of renal 
insufficiency 15. 
Despite its favorable pharmacologic profile, CLZ has not been specifically assessed in SE 
trials, and there are no available observational studies comparing these three medications to 
support the current widespread use of CLZ outside North America. In order to evaluate the 
efficacy of intravenous CLZ as a first line drug in SE treatment compared to intravenous LZP 
and MDZ, we analyzed a multicenter prospective cohort of patients with SE. 
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Methods: 
• Primary research question: 
The primary research question is to compare practice variability in the use of BZDs 
and efficacy of CLZ, LZP and MDZ as a first line agent in SE management. 
• Cohort and SE definition: 
Clinical data were prospectively collected in an observational cohort of consecutive 
adult patients (>16 years) with SE of all etiologies (except post-anoxic SE) admitted 
to four university tertiary care centers, from February 1st 2013 at the Centre 
Hospitalier Universitaire Vaudois, Lausanne, Switzerland; from June 1st 2013 at the 
Brigham and Women’s Hospital and the Massachusetts General Hospital, Boston, 
USA; and from November 1st 2013 at the Beth Israel Deaconess Medical Center, 
Boston, USA, all through March 31, 2014. Because all patients with suspected SE at 
each institution have electroencephalograms (EEGs) within 24 hours, subjects were 
screened through daily review of all EEGs ordered during that period. VA (for the 
centers in Boston) and AOR (at the CHUV) checked inclusion criteria for each subject 
and collected the data prospectively and on a daily basis. Both authors have a 
longstanding collaboration in SE registry16,17,18, helping to assure uniformity in data 
collection. SE was defined as the occurrence of an ongoing epileptic seizure or 
repeated epileptic seizures, without full recovery between seizures for more than 5 
min5. EEG diagnosis was required for non-convulsive SE in accordance to recently 
published criteria19.  
We identified every patient for whom iv CLZ, LZP or MDZ was administered as first 
line treatment. Intravenous CLZ is approved in Switzerland for the treatment of SE 
and is the drug of choice used in the CHUV. LZP is the first line drug most commonly 
used in the three hospitals in Boston, and is also available in Switzerland. MDZ is an 
alternative drug used in all centers. 
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• Local treatment protocols/recommendations:  
The four involved centers have anti-seizure treatment protocols/recommendations 
based on current guidelines and recommendations 5, 20 including:  
• An emergent initial therapy of a benzodiazepine (or 1st line):  
o For the CHUV: CLZ 0.015 mg/kg or MDZ 0.15 mg/kg or LZP 0,1 
mg/kg, with CLZ being preferred 
o Fort the Boston centers:  LZP 0.1 mg/kg or diazepam (DZP) 0.25 
mg/kg or MDZ 0.15 mg/kg, with LZP being preferred 
• An urgent seizure control therapy (or 2nd line): 
o In the four centers: phenytoin (PTH)/fosphenytoin (fPTH) 20 mg/kg or 
valproic acid (VPA) 20-30 mg/kg or levetiracetam (LEV) 20-30 mg/kg 
(or phenobarbital 10-20 mg/kg at 50-100mg/min for US centers only) 
• Refractory SE management (> 30 minutes) (or 3rd line): 
o In case of convulsive SE: Coma induction with MDZ and/or propofol or 
barbiturates 
o In case of focal SE without severe consciousness impairment: addition 
of non-sedative anti-seizures drugs: PTH/fPTH 20 mg/kg OR VPA 20-
30 mg/kg OR LEV 20-30 mg/kg OR lacosamide (LCM) 200-400mg.  
• Definition of variables 
Demographics recorded included age and gender. Worst seizure type was 
categorized as focal seizure with consciousness impairment, focal seizure without 
consciousness impairment, generalized convulsive seizures, absence seizures, 
myoclonic seizure21 and non-convulsive SE in coma (NCSEC). Level of 
 Alvarez, 6 
consciousness before treatment was defined as followed: alert, confused, somnolent 
(arousable with clear contact), stuporous (arousable without contact) and comatose22. 
The STatus Epilepticus Severity Score (STESS) was calculated for every patient 
using age (< 65 years = 0 pt; ≥ 65 years = 2 pts), seizure type (simple-partial, 
complex-partial, absence and myoclonic in the context of idiopathic/genetic epilepsy 
= 0 pt; generalized-convulsive = 1 pt; non-convulsive SE in coma = 2 pts), level of 
consciousness (alert, somnolent or confused = 0 pt; stuporous or comatose = 1 pt), 
and history of previous seizures (yes = 0 pt; no = 1 pt), with a total score between 0 
and 6 points23. The beginning of the SE was determined as precisely as possible 
using pre-hospital chart and emergency department summary. The last observed 
time of good health was considered as the beginning of the SE for episodes without 
clear onsets (unwitnessed, subtle non-convulsive SE). Each treatment line, including 
out of hospital medication was prospectively recorded using pre-medical, emergency 
and in-hospital patient records, including the drug used, total loading dose (repeated 
doses given before the introduction of the next line of treatment was considered as a 
total loading dose), maintenance dose (highest prescribed dose) and timing of 
administration.  
A sufficient loading dose for the first line treatment was defined by at least 0.1 mg/kg 
of LZP, 0.015 mg/kg of CLZ and 0.15 mg/kg of MDZ, in accordance with the currently 
recommended dosages5,24. Second-line treatment was considered adequate if the 
patient received a loading dose of PHT/fPHT (at least 20 mg/kg), VPA (at least 20 
mg/kg), LEV (at least 20 mg/kg), or LCM (at least 200 mg)5. For both first and second 
line agent dosages, a 25% range of deviance from current guidelines was tolerated, 
as previously described18.  
The end of SE episode was defined by the last observed seizure (clinical and/or 
electrographic) without recurrence for at least 48 hours off sedation. SE duration was 
defined as the time between the beginning of SE and the end of SE. Etiology was 
categorized as potentially fatal if not treated, or not, as previously described22,25. 
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Clinical outcome at hospital discharge was categorized as return to pre-morbid 
clinical state, new morbidity, and death. Length of hospital stay in survivors was also 
recorded. 
• Primary and secondary outcomes 
Primary outcomes for first line agent comparisons included: (1) the risk of developing 
refractory SE, defined as failure to respond to an initial benzodiazepine dose followed 
by a second recommended ASD (in other words, need for additional treatment after 
the first and second line treatments in order to control seizures), and (2) the number 
of ASDs needed to control the SE, categorized into three groups: 1 or 2 ASDs, 3 or 4 
ASDs, and 5 or more ASDs. These outcomes were chosen because they are 
objective, and the success of first line benzodiazepine is difficult to assess in an 
observational study due to the common practice of rapid administration of an 
additional non-sedating ASD. Mortality was assessed as a secondary outcome. 
• Standard Protocol Approvals: 
The Institutional Review Boards of each center approved this study. As this 
observational study involved no risk for patients and focused on acute phase of 
critically ill patients, consent was waived. 
• Statistical analysis 
Data were analyzed using Stata 13.1 (StataCorp, College Station, Texas, USA). CLZ, 
LZP and MDZ groups were compared using χ2, Fisher’s exact, ANOVA and Kruskal-
Wallis tests, as required.  
Univariate analyses including first line medication and clinically relevant variables for 
prognosis (sufficient loading dose of first line agent, time to treatment (min), adequate 
second line treatment, STESS, and potentially fatal etiology) were conducted to 
assess effects on primary and secondary outcomes. Variables with a p value < 0.2 
were entered into stepwise logistic or ordered logistic models. Patients without a 
second line treatment were excluded from the refractory SE assessment, because 
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this outcome was not reached in this subgroup. Results were considered statistically 
significant with p < 0.05.  
 
Results:  
Among 238 patients included in the study period, 177 (74.46 %) received iv LZP, MDZ or 
CLZ as a first line drug therapy; groups characteristics are detailed in Table 1. CLZ was used 
in 72 patients (40.62%), LZP in 82 patients (46.33%) and MDZ in 23 (12.99%). In the 61 
other subjects, first line drugs included LEV in 33 (54.1%), PHT/fPHT in five (8.2%), propofol 
in five (8.2%), DZP in four (6.6%), clobazam in two (3.3%), VPA in two (3.3%), LCM in two 
(3.3%), and one each (1.3%) carbamazepine and phenobarbital. In six patients, SE ceased 
spontaneously prior to any treatment. 
Median age, gender, SE severity evaluated with the STESS, and prevalence of a potentially 
fatal etiology were similar across the three groups. More than half of the episodes were 
generalized convulsive in all groups, with a trend towards higher incidence in the MDZ group. 
Suppl. Table 1 (see in supplementary material) provides a list of the underlying etiologies of 
SE. The median time to treatment was similar, but the first line treatment loading dose was 
considered sufficient significantly more often in the CLZ group than in the LZP and MDZ 
groups (p<0.001). Significantly more SE became refractory in the LZP group (p<0.001). The 
rate of the adequacy of the second line treatment was also lower in the LZP and MDZ groups 
(p<0.001). While about 15% of patients needed to be treated with coma induction (without 
significant differences across groups), a greater number of ASDs was needed to control the 
SE in the LZP group (p < 0.001). Median duration of SE was significantly longer in the LZP 
group (p = 0.003). Length of hospital stay and mortality rates was similar among the three 
groups. 
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Demographics, STESS, worse seizure type and time to treatment among the four different 
centers are displayed in Table 2. Except for age, with patients being somewhat younger at 
the BWH, patient and SE characteristics and also time to treatment were similar. 
Table 3 displays practice variability regarding initial dosage and relation between dosage 
adequacy and the three outcomes of interest. It shows that under-dosing is observed in the 
vast majority of cases over the three different sites using LZP, with a similar rate (84%, 95% 
and 87.5%). While status severity (using the STESS) seems similar overall, under-dosed 
patients were significantly older in the LZP group (p=0.04). In the outcome analysis, only the 
rate of refractory SE was significantly different in the LZP group with 60% of refractory SE in 
the group of patients receiving a recommended dosage and 86.11% in the under-treated 
patients. 
Details regarding the relationship between selected variables and the refractoriness of the 
SE are shown in Table 4. After adjustment for the loading dose, LZP, as compared to CLZ, 
remained associated with a higher risk of refractoriness (OR: 6.4, 95% CI: 2.66 – 15.5, 
p<0.001), while there was no difference between CLZ and MDZ. The same results were 
obtained when analyzing convulsive SE only; LZP, as compared to CLZ, remained 
associated with a higher risk of refractoriness (OR: 13, 95% CI: 2.65 – 63.62, p=0.002), while 
there was no difference between CLZ and MDZ. Table 5 shows patients stratified regarding 
the number of ASDs needed to control their SE. After adjustment for the loading dose and 
second line treatment adequacy, LZP was associated with a higher number of ASDs required 
to control SE as compared to CLZ (OR: 4.35, 95% CI: 1.8 - 10.49, p=0.001), while again 
there was no difference between CLZ and MDZ. After adjustment for first line treatment (drug 
choice and loading dose), an adequate dose of second line treatment was associated with a 
lower number of ASDs (OR: 0.47, 95% CI: 0.23 - 0.88, p=0.02). The same results were 
obtained when analyzing convulsive SE only; LZP was associated with a higher number of 
ASDs required to control convulsive SE as compared to CLZ (OR: 5.1, 95% CI: 1.47 – 17.6, 
p=0.01), without any difference between CLZ and MDZ. An adequate dose of second line 
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treatment was associated with a lower number of ASDs (OR: 0.21, 95% CI: 0.08 - 0.57, 
p=0.002) also for the convulsive form only. Table 6 shows that first and second line 
treatments do not significantly influence mortality, as opposed to etiology and the STESS. 
Focusing on convulsive SE only, etiology was the only significant predictor of mortality. 
Discussion: 
While there is robust class I evidence for the use of LZP and MDZ as first line agents in SE 
treatment8,9,10,26 this study provides class III evidence that CLZ is also effective. After 
correction for several major outcome predictors, LZP was associated with a higher risk of 
refractoriness and a greater number of ASDs to control SE as compared to the CLZ, while 
the efficacy of CLZ and MDZ seem comparable. Of note, these findings represent an 
analysis of all types of SE; subgroup analysis of generalized convulsive form only was 
similar. 
These findings have significant implications for clinical practice. Currently, CLZ is absent 
from the current American5 and European6 SE treatment guidelines, although it is available 
and used widely in many countries worldwide in its intravenous form, even while data 
regarding its efficacy are sparse. An older study performed in 61 institutionalized patients 
with refractory epilepsy presenting repeated episodes of SE showed that LZP (4 to 10 mg iv) 
and CLZ (1 mg iv) were comparable to control SE; LZP was more effective in treating EEG 
abnormalities, but CLZ was associated with better clinical responses27. An analysis on 17 
children found that 0.25mg – 0.75mg of iv CLZ was safe and effective in treating SE28. More 
recently, a single-center retrospective assessment of 167 SE episodes found that CLZ was 
the most effective first line therapy, with a success rate of 50%, as compared to 29% for LZP 
or 18% for diazepam29. The favorable pharmacological profile of CLZ, including its high 
lipophily and GABAa affinity, and its long half-life13,14 may account for its efficacy. It may 
provide a longer duration of seizure control between the CLZ and the second line drug by 
means of a synergistic effect on seizure cessation, and avoid seizure recurrence in the acute 
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setting. In this study, the LZP loading dose was found to be insufficient in more patients than 
those receiving other BZDs, but we adjusted for this finding in the statistical analysis. Drugs 
administration rates may explain in part these differences between LZP and the two others 
agents. CLZ and MDZ are given as rapid iv bolus (< 30 seconds) whereas LZP is 
administered at a slower rate (2 mg/min)5. Also, CLZ enters the brain more rapidly after iv 
administration than LZP (10 second – 1 minute vs. 2 - 3 minutes)30. The rapid action of CLZ 
was demonstrated in another uncontrolled study, with a mean time of 1.75 min between 
bolus injection of 1-2 mg CLZ and seizure control, without any major side effects31. While 
LZP has to be stored at 4-8°C, CLZ may be kept at ambient temperature. This represents a 
practical advantage. 
Despite the differences in intermediate outcomes (refractoriness, and number of ASDs 
required to control the SE), the choice of first line BZD treatment did not influence mortality. 
Etiology and SE characteristics (reflected by the STESS) have major prognostic impacts, as 
previously described22,32,33,34,35. Similar findings were found previously when comparing 
differences in second-line ASDs16, likely reflecting the major influence of etiology and SE 
characteristics, compared to the relatively limited effect of the individual anti-seizure drugs on 
mortality18. Nevertheless, a faster resolution of SE is associated with a shorter hospital stay7, 
and differences in SE refractoriness or in the number of ASDs needed to stop SE may have 
consequences for complications, resource utilization, and cost. 
Another important finding is that current treatment guidelines are relatively poorly followed. 
Only three quarters of the patients received one of the locally recommended BZD as first line 
therapy. While a small minority (6 patients) not treated according to protocol received an 
alternative BZD, most of them were managed with an agent usually recommended as a 
second line. Similar results were found in a SE management survey performed in 15 US 
hospitals7 with 74.7% of patient receiving a BZD as the first treatment. Moreover, the dose of 
the first line drug was determined to be sufficient in only 41% of cases in our cohort similar to 
previous findings. One study in France found a 62% rate of non-adherence to the local 
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protocol for first line treatment36. In 75.8% of patients in an American cohort, the dose of the 
first ASD administered was less than recommended37. In another study, only 20% of SE 
treatments were considered adequate in a tertiary care setting and in 52% in a rural area in 
Italy4. The non-adherence to treatment protocols already observed in several countries may 
also explain the relative high rate of initial treatment failure as opposed to randomized trials. 
Effort in education of SE management and treatment protocols seems thus necessary. 
The apparent under-dosage of LZP as first line treatment for SE was particularly marked in 
our study with a constant rate among the different involved centers. The exact protocol-
mandated doses might explain much of this difference: while a CLZ dose of 0.015 mg/kg 
may appear more difficult to calculate than the 0.1 mg/kg required for LZP, the usually 
prescribed 1-1.5 mg of CLZ is equal to the required dose for an adult of average weight (65-
100 kg). On the other hand, the equivalent dose of 6.5-10 mg of LZP is hardly ever achieved. 
Indeed, by most protocols, LZP is given in a slow infusion, up to 4 mg per dose, repeated as 
needed5. In our cohort, administrations of 4 mg were infrequently used and rarely repeated. 
Our findings suggest that this issue appears more marked for older patients. These 
considerations are important given that adequate first line treatment is strongly associated 
with interruption of SE5,36.  
The strengths of this study include the large number of patients and their prospectively 
collected data in US and European centers with large experience in SE management. There 
are, however, some limitations. The major limitation is that all patients receiving CLZ were 
treated in Switzerland, and all patients in the LZP group in the three US hospitals, so we 
cannot exclude the possibility of some unrecognized confounders due to a deterministic 
association between site and the choice of the agent. Nevertheless, the three BZD treatment 
groups were very similar in demographics, SE characteristics, SE severity, and etiology, 
rendering a major selection and information bias unlikely. Also, all four participating centers 
have 24/7 onsite Neurology consult teams available; in-patient Neurology and intensive care 
units admitting patients 24/7; and SE treatment protocols based on current guidelines. 
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Moreover the four involved centers included similar patients regarding SE severity, seizure 
type and delay between SE and first treatment. The only salient difference in the 
management of these patients is the use of continuous EEG monitoring, performed only in 
selected cases in the CHUV (which favors repeated routine EEGs), while routinely applied in 
the US hospitals. Consequently, purely electrographic seizures may have been missed in 
Switzerland, and this might have influenced estimations of SE duration. For this reason, SE 
duration was not considered as an outcome in comparing the three drugs. The impact on 
refractoriness and the number of ASDs needed seems low. Because of the EEG screening 
process, we cannot exclude the possibility that some short SE episodes that respond rapidly 
to an initial first line treatment with benzodiazepines were not included. Also data collection 
was performed by two investigators involved in the project and not by persons blinded to the 
purpose of the study. Because of this we cannot exclude some bias in data collection. 
However, data were collected as objectively as possible and the outcomes (refractoriness, 
number of needed ASDs and mortality) are clear and objective measurements. The rate of 
success of BZDs stopping SE was lower in this study than in several trials8,9,10,26. This is, 
however, a frequent finding in observational studies7,16,29 ,36 and may be explained by the 
common clinical practice of the rapid use of a non-sedating drug with the first line BZD7 
(which renders the first line efficacy assessment difficult and unreliable), and also by our 
definition of SE control as 48 hours without seizure recurrence, as opposed to convulsion 
cessation in the emergency department in many prospective trials. This also underscores a 
marked difference between the aforementioned randomized control trials, which enrolled 
selected patients with generalized SE, and the real world clinical practice reflected by our 
observational assessment, which was not limited to convulsive SE; we therefore feel that our 
findings may be more widely generalizable. Admittedly, the success rate of the first line agent 
alone could thus not be assessed as an outcome. Moreover, due to the observational nature 
of this study and despite treatment protocols, there is inevitable heterogeneity in treatment 
regimens. However, we adjusted for BZD and for second line treatment adequacy (as 
compared to treatment guidelines) in the multivariate analysis. Adverse effects, including 
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need for ventilation and hypotension, were not collected systematically, so we were unable to 
compare the safety of these three drugs. This would need further evaluation in future studies. 
Nevertheless, CLZ has been proven to be safe in this setting for several decades28,31, as it is 
in our clinical experience. Finally, it is possible that tertiary care hospital settings may confer 
a selection bias toward the inclusion of patients with more severe SE, but we do not believe 
that this would affect the comparison of the three medications. 
Conclusion: 
Our study provides class III evidence for the efficacy of intravenous CLZ as a first line 
treatment for status epilepticus. Its efficacy may be similar to that of MDZ and even higher 
than with LZP, although other treatment factors at the different centers could also explain 
differences in outcome among the benzodiazepine treatment groups. While LZP is 
considered the first line treatment for SE in several protocols and countries, CLZ has a 
favorable pharmacologic profile and is used in many other countries, although to date, 
without strong supporting evidence. The second important finding is that LZP is frequently 
under dosed. Since SE requires rapid and adequate treatment to stop seizures, our data may 
suggest that treatment protocols may need better education. CLZ may be more effective at 
least in part because its simpler dosing (vis a vis those used for LZP and MDZ), which may 
improve adherence to treatment protocols. While a randomized controlled trial seems 
warranted to confirm our findings based on observational data, inclusion of intravenous CLZ 
in international SE treatment guidelines (which base their 2nd and 3rd line treatment 
recommendations on expert opinions and case series) seems reasonable. 
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Summary: 
• Clonazepam seems to be an effective alternative to lorazepam and midazolam as 
first line treatment of status epilepticus. 
• Lorazepam is under dosed in the majority of cases. 
• Practice variability of initial treatment influences the risk of refractoriness and the 
number of anti-seizure drugs used but not outcome at hospital discharge. 
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TABLES:  
1: Demographic, SE characteristics, etiology, treatments and clinical outcome according to the first line treatment drug 
    TOTAL  CLZ  LZP  MDZ  p test 
 n, % 177 100  72 40.68  82 46.33  23 12.99    
Demographics and SE characteristics      
Age mean, SD 56.79 19.66  59.59 21.71  55.57 16.4  52 22.8  0.21 ANOVA 
Male gender n, % 91 51.44  42 58.33  39 47.56  10 43.48  0.29 χ
2 
STESS mean, SD 2.58 1.62  2.79 1.65  2.36 1.68  2.73 1.21  0.23 ANOVA 
Potentially fatal etiology n, % 77 43.5  30 41.67  37 45.12  10 43.38  0.91 χ
2 
Started pre-hospital n, % 138 77.97  54 75.00  62 75.61  22 95.65  0.09 χ
2 
Worst seizure type n, %               
• Absence 1 0.56  1 1.39  0 0  0 0    
• Myoclonic 1 0.56  1 1.39  0 0  0 0    
• Focal without consc. Impairment 18 10.17  8 11.1  9 10.98  1 4.35    
• Focal with consc. Impairment 49 27.68  22 30.56  23 28.05  4 17.39    
• Generalized convulsive 99 55.93  38 52.78  44 53.66  17 73.91    
• Non-convulsive in coma 9 5.08  2 2.78  7 7.32  1 4.35  0.635 Fisher 
SE duration (h)	 median, range 27.8 0 – 408  9.5 0.37 - 408  50 0 – 312  4 0.5 – 209  0.003 Kruskal-Wallis 
Refractory SE n, % 108 61.02  31 43.06  68 82.93  9 39.13  <0.001 χ
2 
 Treatment Characteristics                 
Time to treatment (min) median, range 60 5 - 7200  92.5 5 - 4320  50 5 - 7200  60 10 - 2880  0.277 Kruskal-Wallis 
First line loading dose (mg) median, range                     - -  1 0.25 - 7.5   2 1 - 12   7.5 1.5 - 30   - -  
Sufficient dose of first line drug n, % 73 41.24  52 72.22  10 12.2  11 47.83  <0.001 χ
2 
Adequate second line treatment 
(when needed) n, % 81/156 51.92  41/59 69.49  36/76 47.37  4/21 19.05  <0.001 χ
2 
Intubation for SE control n, % 26 14.69  7 9.72  16 19.51  3 13.04  0.223 Fisher 
Number of ASDs needed to 
terminate SE mean, SD 3.21 1.48  2.69 1.38  3.73 1.41  3 1.47  <0.001 ANOVA 
                
Outcomes at hospital discharge:               
Return to clinical base line n, % 82 46.33  35 48.61  31 37.8  16 69.57    
New Morbidity  75 42.37  29 40.28  40 48.78  6 26.09    
Death  20 11.2  8 11.11  11 13.41  1 4.35  0.12 Fisher 
Length of hospital stay (d) for 
survivors median, range 8.21 0 - 72  8.55 0 - 72  9 1.94 - 60.03  7.23 0 - 40.29  0.913 Kruskal-Wallis 
 
Abbreviations:  
ASD: anti-seizure drugs, CLZ: clonazepam, consc: consciousness, LZP: lorazepam, MDZ: midazolam, min: minutes, mg: milligram, SD: standard deviation, SE: status epilepticus, STESS: STatus 
Epilepticus Severity Score. In Bold: statistically significant
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Table 2: Demographics, status epilepticus characteristics and time to treatment among the four involved centers 
 
    CHUV  BWH  MGH  BIDMC  p test 
 n, % 91 51.41  52 29.4  14 14.12  9 5.1    
Demographics and SE characteristics      
Age mean, SD 57.9 22.5  50.1 14.6  62.7 15.9  64.8 14  0.03 ANOVA 
Male gender n, % 51 56.04  20 38.5  14 56  6 66.7  0.15 χ
2 
STESS mean, SD 2.79 1.57  2.11 1.55  2.84 1.59  2.77 2.2  0.1 ANOVA 
Potentially fatal etiology n, % 37 40.6  21 40.38  16 64  3 33.4  0.16 χ
2 
Started pre-hospital n, % 70.3 80.22  39 75  19 76  7 77.8  0.89 χ
2 
Worst seizure type n, %               
Absence 1 1.1  0 0  0 0  0 0    
Myoclonic 1 1.11  0 0  0 0  0 0    
Focal without consc. Impairment 9 9.9  7 13.5  2 8  0 0    
Focal with consc. Impairment 26 28.6  10 19.2  10 40  3 33.3    
Generalized convulsive 52 57.14  31 59.52  12 48  4 44.4    
Non-convulsive in coma 2 2.2  4 7.7  1 4  2 22.2  0.49 χ
2 
 Treatment Characteristics                 
Time to treatment (min) median, range 90 5 - 4320  50 5 – 7200  55 5 – 2340  75 5 – 2820  0.45 Kruskal-Wallis 
 
Abbreviations:  
BIDMC: Beth Israel Deaconess Medical Center, BWH: Brigham and Women’s Hospital, CHUV: Centre Hospitalier Universitaire Vaudois, consc: consciousness, MGH: Massachusetts General 
Hospital, min: minutes, SD: standard deviation, STESS: STatus Epilepticus Severity Score. In Bold: statistically significant 
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Table 3: Analysis of practice variability, age, status epilepticus severity and outcome association regarding first line treatment dosage adequacy 
for clonazepam, lorazepam and midazolam 
  CLZ p (test)  LZP p (test)  MDZ p (test) 
  Adequate 
dose 
Insufficient 
dose 
  Adequate 
dose 
Insufficient 
dose 
  Adequate 
dose 
Insufficient 
dose 
 
N  52 20   10 72   11 12  
             
Center n (%)            
  CHUV  52 (72.22)* 20 (27.78)*   0 (0)* 0 (0)*   11 (57.89)* 8 (42.11)*  
  BWH  0 (0) 0 (0)   8 (16) 42 (84)   0 (0) 2 (100)  
  MGH  0 (0) 0 (0)   1 (4.17) 23 (95.83)   0 (0) 1 (100)  
  BIDMC  0 (0) 0 (0) n/a  1 (12.5) 7 (87.5) 0.34 (Fisher)  0 (0) 1 (100) 0.205 (Fisher) 
             
Age mean (SD) 57.6 (21.7) 64.9 (21.3) 0.2 (t-test)  46.1 (11.9) 57 (16.6) 0.04 (t-test)  46.5 (27.7) 57 (17.1) 0.28 (t-test) 
             
STESS mean (SD) 2.86 (1.53) 2.6 (1.95) 0.54 (t-test)  2.2 (0.42) 2.38 (1.78) 0.74 (t-test)  2.36 (1.2) 3 (1.16) 0.16 (t-test) 
             
Refractory SE n (%) 25 (48.8)** 6 (30)** 0.165 (χ2)  6 (60)** 62 (86.1)** 0.04 (χ2)  4 (36.36)** 5 (41.67)** 0.795 (χ2) 
             
Number of 
ASD 
n (%)            
   0-2  23 (44.23)** 13 (65)**   3 (30)** 10 (13.9)**   5 (45.45)** 6 (50)**  
   3-4  23 (44.23) 6 (30)   5 (50) 42 (58.33)   6 (54.44) 2 (16.67)  
   ≥5	  6 (11.54) 1 (5) 0.362 (Fisher)  2 (20) 20 (27.78) 0.47 (Fisher)  0 (0) 4 (33.33) 0.07 (Fisher) 
             
Mortality  4 (7.69)** 4 (20)** 0.137 (χ2)  1 (10)** 10 
(13.89)** 
1 (Fisher)  0 (0)** 1 (8.33)** 1 (Fisher) 
 
*: Raw percentage 
**: Column percentage 
Abbreviations:  
ASD: anti-seizure drug, BIDMC: Beth Israel Deaconess Medical Center, BWH: Brigham and Women’s Hospital, CHUV: Centre Hospitalier Universitaire Vaudois, MGH: 
Massachusetts General Hospital, SD: standard deviation, STESS: STatus Epilepticus Severity Score. In Bold: statistically significant 
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Table 4: Clinically relevant variables and their association with refractory SE (univariate analysis and after logistic regression), excluding 
patients with no administration of a second line ASD. Analyses were performed for the whole cohort and for convulsive status epilepticus only. 
		 	
	
Univariate	Analysis:	 		 		 Multivariate	Analysis:	
		 	
	 	 	 	 	 	 	 	
	
	 Total	 No	Refractory	SE	 Refractory	SE	 p	(test)	 	 OR	 95%	CI	 p	
Total	 n	(%)	 156	 49	(31.34)	 107	(68.59)	 	 	 	 	 	
First	line	 	 	 	 	 	 	 	 	 	
CLZ	 n	(%)	 57	 29	(49.15)	 30	(50.85)	 	 	 Ref.	 	 	
LZP	 n	(%)	 76	 8	(10.53)	 68	(89.47)	 	 	 6.4	 2.66	–	15.5	 <0.001	
MDZ	 n	(%)	 21	 12	(57.14)	 9	(42.86)	 <0.001*	(χ2)	 	 0.85	 0.31	–	2.26	 0.995	
Time	to	treatment	(min)	 median	(range)	 60	(5	–	7200)	 60	(5	-	4320)	 60	(5	-	7200)	 0.498	(Wilcoxon)	 	 	 	 	
Sufficient	dose	of	first	line	drug	 n	(%)	 60	 26	(43.33)	 34	(56.67)	 0.011*	(χ2)	 	 1	 0.45	–	2.2	 0.995	
Adequate	second	line	 n	(%)	 81	 27	(33.33)	 54	(66.67)	 0.591	(χ2)	 	 	 	 	
STESS	 mean	(SD)	 2.69	(1.62)	 2.87(1.57)	 2.61	(1.64)	 0.35	(t-test)	 	 	 	 	
Potentially	fatal	etiology	 n	(%)	 70	 23	(32.86)	 47	(67.14)	 0.725	(χ2)	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
Convulsive	SE	only	 n	(%)	 85	 28	(32.94)	 57	(67.06)	 	 	 	 	 	
First	line	 	 	 	 	 	 	 	 	 	
CLZ	 n	(%)	 38	 17	(54.84)	 14	(45.16)	 	 	 Ref.	 	 	
LZP	 n	(%)	 44	 3	(7.69)	 36	(92.31)	 	 	 13	 2.65	–	63.62	 0.002	
MDZ	 n	(%)	 17	 8	(53.33)	 7	(46.67)	 <0.001*	(χ2)	 	 1.01	 0.26	–	3.9	 0.982	
Time	to	treatment	(min)	 median	(range)	 45	(5	–	2880)	 65	(5	–	2880)	 40	(5	–	2820)	 0.09*	(Wilcoxon)	 	 0.99	 0.99	–	1	 0.199	
Sufficient	dose	of	first	line	drug	 n	(%)	 38	 18	(47.37)	 20	(52.63)	 0.011*	(χ2)	 	 0.69	 0.19	–	2.43	 0.367	
Adequate	second	line	 n	(%)	 38	 15	(39.47)	 23	(60.53)	 0.24	(χ2)	 	 	 	 	
STESS	 mean	(SD)	 3.16	(1.29)	 3.21	(1.25)	 3.14	(1.32)	 0.8	(t-test)	 	 	 	 	
Potentially	fatal	etiology	 n	(%)	 34	 11	(39.29)	 23	(40.35(	 0.925	(χ2)	 	 	 	 	
 
*: Used in regression model because p<0.2 
Abbreviation:  
CI: confidence intervals, CLZ: clonazepam, LZP: lorazepam, MDZ: midazolam, mulitvar: multivariate, OR: odds ratio, ref: reference, SE: status epilepticus, STESS: STatus Epilepticus Severity Score 
In Bold: statistically significant 
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Table 5: Clinically relevant variables and their association with the number of ASDs needed to control the SE (univariate analysis and after 
ordered logistic regression). Analyses were performed for the whole cohort and for convulsive status epilepticus only. 
		 	
	
Univariate	Analysis:	 		 		 Multivariate	Analysis:	
		 	
	 	 	 	 	 	 	 	 	
	
	 Total	 1-2	ASDs	needed	 3-4	ASDs	needed	 ≥5	ASDs	needed	 p	(test)	 	 OR	 95%	CI	 p	
Total	 n	(%)	 177	 60	(33.9)	 84	(47.46)	 33	(18.64)	 	 	 	 	 	
First	line	 	 	 	 	 	 	 	 	 	 	
CLZ	 n	(%)	 72	 36		(50)	 29	(40.28)	 7	(9.72)	 	 	 Ref.	 	 	
LZP	 n	(%)	 82	 13	(15.85)	 47	(57.32)	 22	(26.83)	 	 	 4.35	 1.8	-	10.49	 0.001	
MDZ	 n	(%)	 23	 11	(47.83)	 8	(34.78)	 4	(17.39)	 <0.001*	(χ2)	 	 0.73	 0.25	-	2.16	 0.577	
Time	to	treatment	(min)	 median	(range)	 60	(5	–	7200)	 80	(5-4320)	 66	(5-7200)	 50	(5-2340)	 0.389	(Kruskal-Wallis)	 	 	 	 	
Sufficient	dose	of	first	line	drug	 n	(%)	 74	 31	(42.47)	 34	(46.58)	 8	(10.96)	 0.036*	(χ2)	 	 1.39	 0.63	-	3.05	 0.409	
Adequate	second	line	 n	(%)	 81	 25	(30.86)	 45	(55.56)	 11	(13.58)	 0.031*	(χ2)	 	 0.45	 0.23	-	0.88	 0.02	
STESS	 mean	(SD)	 2.58	(1.62)	 2.53	(1.69)	 2.59	(1.58)	 2.66	(1.63)	 0.934	(ANOVA)	 	
	 	
		
Potentially	fatal	etiology	 n	(%)	 77	 26	(33.77)	 40	(51.95)	 11	(14.29)	 0.374	(χ2)	 	 		 		 		
	 	 	 	 	 	 	 	 	 	 	
Convulsive	SE	only	 n	(%)	 99	 34	(34.34)	 46	(46.46)	 19	(19.19)	 	 	 	 	 	
First	line	 	 	 	 	 	 	 	 	 	 	
CLZ	 n	(%)	 38	 19	(50)	 17	(44.74)	 2	(5.26)	 	 	 Ref.	 	 	
LZP	 n	(%)	 44	 7	(15.91)	 23	(52.27)	 14	(31.82)	 	 	 5.1	 1.47	–	17.6	 0.01	
MDZ	 n	(%)	 17	 8	(47.06)	 6	(35.29)	 3	(17.65)	 0.003*	(χ2)	 	 0.56	 0.13	–	2.38	 0.439	
Time	to	treatment	(min)	 median	(range)	 45	(5	–	2880)	 50	(5	–	2880)	 42.5	(5	–	2820)	 30	(5	–	390)	 0.89	(Kruskal-Wallis)	 	 	 	 	
Sufficient	dose	of	first	line	drug	 n	(%)	 47	 21	(44.68)	 22	(46.81)	 4	(8.51)	 0.017*	(χ2)	 	 0.77	 0.27	–	2.2	 0.63	
Adequate	second	line	 n	(%)	 38	 13	(34.21)	 22	(57.89)	 3	(7.89)	 0.007*	(χ2)	 	 0.21	 0.08	–	0.57	 0.002	
STESS	 mean	(SD)	 3.03	(1.31)	 3	(1.37)	 3.13	(1.24)	 2.84	(1.42)	 0.813	(ANOVA)	 	
	 	
		
Potentially	fatal	etiology	 n	(%)	 37	 11	(29.73)	 20	(54.05)	 6	(16.22)	 0.5	(χ2)	 	 		 		 		
*: Used in regression model because p<0.2 
Abbreviation:  
CI: confidence intervals, CLZ: clonazepam, LZP: lorazepam, MDZ: midazolam, mulitvar: multivariate, OR: odds ratio, ref: reference, SE: status epilepticus, STESS: STatus Epilepticus Severity Score 
In Bold: statistically significant 
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Table 6: Clinically relevant variables and their association with mortality (univariate analysis and after logistic regression). Analyses were 
performed for the whole cohort and for convulsive status epilepticus only. 
		 	 		 Univariate	Analysis:	 		 		 Multivariate	Analysis:	
		 	
	 	 	 	 	 	 	 			 	 	 Deceased	
Alive	at	
discharge	 p	(test)	 	 OR	 95%	CI	 p	
Total		 n	(%)	 177	 20	(11.3)	 157	(88.7)	 	 	 	 	 	
First	line	 	 	 	 	 	 	 	 	 	
CLZ		 n	(%)	 72	 8	(11.11)	 64	(88.89)	 	 	 	 	 	
LZP	 n	(%)	 82	 11	(13.41)	 71	(86.59)	 	 	 	 	 		
MDZ	 n	(%)	 23	 1	(4.35)	 22	(95.65)	 0.478	(χ2)	 	 	 	 		
Time	to	treatment	(min)	 median	(range)	 60	(5	–	7200)	 60	(5	-	4320)	 60	(5	-	7200)	 0.88	(Wilcoxon)	 	 	 	 		
Sufficient	dose	of	first	line	drug	 n	(%)	 73	 5	(6.85)	 68	(93.15)	 0.117*	(χ2)	 	 0.59	 0.18	-	1.86	 0.371	
Adequate	second	line		 n	(%)	 81	 10	(12.35)	 71	(87.65)	 0.854	(χ2)	 	 	 	 		
STESS	 mean	(SD)	 2.58	(1.62)	 3.8	(1.47)	 2.43	(1.57)	 <0.001*	(t-test)	 	 1.64	 1.19	-	2.25	 0.002	
Potentially	fatal	etiology	 n	(%)	 77	 15	(19.48)	 62	(80.52)	 0.003*	(χ2)	 	 3.59	 1.16	-	11.1	 0.026	
	 	 	 	 	 	 	 	 	 	
Convulsive	SE	Only		 n	(%)	 99	 10	(10.1)	 89	(89.9)	 	 	 	 	 	
First	line	 	 	 	 	 	 	 	 	 	
CLZ		 n	(%)	 38	 3	(7.9)	 35	(92.1)	 	 	 	 	 	
LZP	 n	(%)	 44	 6	(13.64)	 38	(86.36)	 	 	 	 	 		
MDZ	 n	(%)	 17	 1	(5.88)	 16	(94.2)	 0.565	(χ2)	 	 	 	 		
Time	to	treatment	(min)	 median	(range)	 45	(5	–	2880)	 42.5	(15	–	360)	 45	(5	–	2880)	 0.75	(Wilcoxon)	 	 	 	 		
Sufficient	dose	of	first	line	drug	 n	(%)	 47	 4	(8.51)	 43	(91.49)	 0.618	(χ2)	 	 	 	 	
Adequate	second	line		 n	(%)	 38	 5	(13.16)	 33	(86.44)	 0.72	(χ2)	 	 	 	 		
STESS	 mean	(SD)	 3.03	(1.31)	 3.8	(1.15)	 2.94	(1.3)	 0.05*	(t-test)	 	 1.45	 0.84	–	2.5	 0.173	
Potentially	fatal	etiology	 n	(%)	 37	 8	(21.62)	 29	(78.78)	 0.003*	(χ2)	 	 6.92	 1.34	–	35	 0.02	
*: Used in regression model because p<0.2 
 
Abbreviation:  
CI: confidence intervals, CLZ: clonazepam, LZP: lorazepam, MDZ: midazolam, mulitvar: multivariate, OR: odds ratio, ref: reference, SE: status epilepticus, STESS: STatus Epilepticus Severity Score 
In Bold: statistically significant.
